Buprenorphine Pharmaceuticals

demand / volume affecting revenue

“Net sales of MFAs and other increased $139.1 million, or 54%, due to incremental revenues of $137.9 million from sales of products from the MFA portfolio acquired on October 31, 2024 and increased demand for certain of our MFAs in North and South America, partially offset by the timing of purchases by a large customer.”

PAHC 10-Q

credit / rates affecting interest expense

“Interest expense, net increased $1.1 million due to the expiration of an interest rate swap agreement.”

PAHC 10-Q

demand / volume

“Disruptions due to a resurgence of COVID-19 or other similar health epidemics could negatively impact our manufacturing facilities, and our logistics and supply chain operations, as well as those of our customers, third-party manufacturers, suppliers and end users of our products who raise animals or who process meat, milk, eggs and seafood for human consumption and may result in a period of economic and business disruption and could have a material adverse impact on our business and financial results. ​ 32 Table of Contents The COVID-19 pandemic and similar outbreaks could lead to decreased demand for protein, which may lead to end users of our products reducing their herd or flock sizes.”

PAHC 10-K